Cocrystallization of multi-kinase inhibitor pazopanib with fenamic acids: improving dissolution and inhibiting cell migration
- 5 September 2023
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in CrystEngComm
- Vol. 25 (39) , 5565-5574
Abstract
A multi-kinase inhibitor, pazopanib (PAZ) is cocrystallized with cyclooxygenase (COX) inhibitor fenamic acids to investigate the dissolution rate and inhibition of cell migration in VEGF-triggered HUVEC cells to test the efficacy of stoichiometric drug–drug combinations. Crystallization experiments at the sub-milligram level in an acetonitrile–methanol mixture yielded two drug–drug salt forms of PAZ with flufenamic acid (FFA) and niflumic acid (NFA) as PAZ+·FFA−·ACN (an acetonitrile solvate named as form I) and PAZ+·NFA−. Structures of the crystal forms were characterized by single crystal X-ray diffraction (SC-XRD) method. Crystal structures revealed that the presence of a 2-aminopyrimidine group in PAZ is a strong partner for the carboxyl group in all solid forms, forming an acid⋯pyrimidine heterosynthon with COX inhibitor fenamic acids. To perform dissolution experiments and cell line analysis, the scale-up of both salt forms were done in the acetonitrile–methanol mixture through crystallization, which showed a polymorphic transformation in the case of PAZ+·FFA−·ACN (an acetonitrile solvate named form II). The thermodynamic stability of PAZ+·FFA−·ACN (form II) and PAZ+·NFA− were analysed using slurry experiment under ambient conditions in pH 1.2 (0.1 N HCl) buffer medium and the residual solid phase was characterized by powder XRD, which showed that PAZ+·FFA−·ACN (form II) was a metastable solid form while PAZ+·NFA− was a stable solid form. The dissolution experiments at gastric pH 1.2 showed that the rate of dissolution of PAZ+·FFA−·ACN was 10 times higher than PAZ+·NFA−. The cell migration assay suggested that PAZ+·FFA−·ACN inhibited ∼25% and PAZ+·NFA− inhibited ∼20% migration of HUVEC cells compared to PAZ alone. These investigations suggested that the drug–drug salts PAZ+·FFA− and PAZ+·NFA− would be potential combo drug candidates for clinical trials.Keywords
Funding Information
- Anusandhan National Research Foundation (SR/S2/JCB-06/2009, SUR/2022/002726)
- University Grants Commission (UGC/26/2601/2017/01285)
- Department of Science and Technology, Ministry of Science and Technology, India (SR/FST/CSII-030/2014/(C))
This publication has 36 references indexed in Scilit:
- Combination therapy in combating cancerOncotarget, 2017
- Development and In Vivo Evaluation of a Novel Histatin-5 Bioadhesive Hydrogel Formulation against Oral CandidiasisAntimicrobial Agents and Chemotherapy, 2016
- Solid state forms of 4-aminoquinaldine – from void structures with and without solvent inclusion to close packingCrystEngComm, 2015
- Crystal structure refinement withSHELXLActa Crystallographica Section C Structural Chemistry, 2015
- Polymorphism in cocrystals: a review and assessment of its significanceCrystEngComm, 2014
- Strategies to Address Low Drug Solubility in Discovery and DevelopmentPharmacological Reviews, 2013
- Acid–base crystalline complexes and the pKa ruleCrystEngComm, 2012
- WinGXandORTEP for Windows: an updateJournal of Applied Crystallography, 2012
- Drug Absorption Interactions Between Oral Targeted Anticancer Agents and PPIs: Is pH-Dependent Solubility the Achilles Heel of Targeted Therapy?Clinical Pharmacology & Therapeutics, 2012
- Structure validation in chemical crystallographyActa Crystallographica Section D Structural Biology, 2009